Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Blood System Drugs (Find 2 items)

Blood System Drugs

Ozagrel

(82571-53-7)
Strong thromboxane synthase inhibitor. By inhibiting thromboxane synthase, it reduces thromboxane A, (TXA2), and promotes the production of prostacyclin (PGl2) to fight platelet aggregation and cerebral vasospasm, and other arachidene such as cyclooxygenase Acid metabolic enzymes have little effect. Clinically used for the treatment of cerebral spasm after subarachnoid hemorrhage and cerebral ischemia accompanied by cerebral spasm, and the improvement of dyskinesia associated with acute stage of

Product List

Request for quotation , get quotes from more suppliers.

Hematological diseases refer to diseases that are primary (such as leukemia) or mainly involve blood (such as iron deficiency anemia) and hematopoietic organs. Classification: red blood cell diseases, such as various types of anemia and polycythemia, etc .; granulocyte diseases, such as leukopenia and agranulocytosis, neutrophil lobular insufficiency, inert leukocyte syndrome, and leukemia-like reactions. Blood system drugs mainly include: anti-anemic drugs, leukocyte-raising drugs, antiplatelet drugs, procoagulant drugs, anticoagulant drugs and thrombolytic drugs, blood volume expansion agents, leukocyte-raising drugs, antiplatelet drugs and other drugs. The "Blood System Drugs" on ECHEMI classification list mainly supplies APIs for these drugs.
Complaint
Email:
Message:
Send Message